التفاصيل البيبلوغرافية
| العنوان: |
Endothelial Dysfunction in Patients with Advanced Heart Failure Treated with Levosimendan Periodic Infusion Compared with Optimal Medical Therapy: A Pilot Study |
| المؤلفون: |
Alessandro Maloberti, Jinwei Sun, Jessica Zannoni, Lucia Occhi, Ilaria Bassi, Saverio Fabbri, Valentina Colombo, Elena Gualini, Michela Algeri, Marisa Varrenti, Gabriella Masciocco, Enrico Perna, Fabrizio Oliva, Manlio Cipriani, Maria Frigerio, Cristina Giannattasio |
| المصدر: |
Life, Vol 12, Iss 9, p 1322 (2022) |
| بيانات النشر: |
MDPI AG, 2022. |
| سنة النشر: |
2022 |
| المجموعة: |
LCC:Science |
| مصطلحات موضوعية: |
endothelial dysfunction, flow-mediated vasodilation, levosimendan, heart failure, Science |
| الوصف: |
Endothelial dysfunction (ED) is frequently found in patients with heart failure (HF). Among several pharmacological agents reported to improve endothelial function, levosimendan seems to be a promising one, even though, to date, only two previously published studies have evaluated its effects on ED in these patients. The aim of our pilot study was to further investigate the role of periodic levosimendan infusion on endothelial function in patients affected by advanced HF. In this cross-sectional study, three different groups were enrolled: 20 patients with advanced HF treated with periodic levosimendan (LEVO), 20 patients with HF on optimal medical therapy (OMT), and 20 healthy subjects (control group). ED was evaluated through flow-mediated dilation (FMD) at the level of the brachial artery. The three groups presented similar ages with significant differences in gender distribution, systolic blood pressure, and chronic kidney disease (eGFR < 30 mL/min). In HF patients, ischaemic aetiology was more prevalent in the LEVO group than in the OMT group (60 vs. 40%, p < 0.001). The New York Heart Association (NYHA) functional class was worse in the LEVO group, as well as in NT-proBNP (5636.7 ± 6164.6 ng/dL and 1243.7 ± 1487.2 ng/dL, in the LEVO and OMT groups, respectively, p = 0.005). The FMD was significantly higher in the healthy control group compared to that of the OMT group (15.7 ± 6.4 vs. 9.1 ± 6.0%, p = 0.007) while it showed an intermediate value in LEVO patients (12.4 ± 7.1%) (ANOVA p = 0.010). In conclusion, levosimendan therapy seems to ameliorate endothelial dysfunction related to heart failure. Longitudinal studies in patients on periodic therapy are needed in order to confirm the long-term effects of levosimendan on ED. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2075-1729 |
| Relation: |
https://www.mdpi.com/2075-1729/12/9/1322; https://doaj.org/toc/2075-1729 |
| DOI: |
10.3390/life12091322 |
| URL الوصول: |
https://doaj.org/article/eb1dc7cbd257414cb1b300f1bc4def47 |
| رقم الانضمام: |
edsdoj.b1dc7cbd257414cb1b300f1bc4def47 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder